Dermazin is a local chemotherapeutic for prevention and treatment of burn wound infections.
Silver sulfadiazine disintegrates in the burn wound, thereby causing a slow and sustained release of silver ions. Silver ions bind to bacterial deoxyribonucleic acid, thus inhibiting the growth and multiplication of bacterial cells without affecting the cells of the skin and subcutaneous tissue. Dermazin cream has a broad antibacterial spectrum including virtually all microbial species likely to infect the burn wound: Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, strains of Proteus and Klebsiella; it is also effective against Candida albicans and other fungi.
Dermazin penetrates into the necrotic tissue and exudates. This effect is very important in view of the fact that systemic antibiotics are not effective against the bacterial flora of the avascular burn necrosis.